Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The associate professor of medicine at the Cleveland Clinic Lerner College of Medicine highlighted the importance of early, multidisciplinary intervention for patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Starting Comprehensive Multiple Sclerosis Care at Initial Diagnosis: Mary R. Rensel, MD, FAAN, ABIHM

Articles

The phase 2 trial tests Roche’s investigational antisense oligonucleotide therapy tominersen in patients with early stages of Huntington disease, a disease with no FDA-approved therapies available.

Examining Tominersen as a Potential Treatment for Huntington Disease: The GENERATION HD2 trial

Gene Therapy, ASOs, and Beyond: What’s Coming for Huntington’s Disease

Neurology News Network. for the week ending May 31, 2025. [WATCH TIME: 4 minutes]

ADDRESS-LC Study of Long COVID Initiated, Phase 4 Trial Testing IVIg Transition to Efgartigimod, Lack of Rebound Effect Seen in Ozanimod

Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine; Director, Pediatric Multiple Sclerosis and Wellness, Mellen Center, Cleveland Clinic; Founder, Brain Fresh

Host Jeffrey Wilken, PhD, chats with Riley Bove, MD, about the third day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

CMSC Live: 2025 Annual Meeting Day 3

AHN Saint Vincent Hospital offers advanced neurological care, reducing wait times and providing local access to specialized treatments for various conditions.

Neuroscience at AHN Saint Vincent: Advanced Treatments and Collaborative Care Closer to Home

Host Jeffrey Wilken, PhD, chats with Anthony Feinstein, MPhil, PhD, FRCP, about the second day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

CMSC Live: 2025 Annual Meeting Day 2

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1.125rem

Clinical

 Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Medcast Podcasts

Optimizing Parkinson's disease (PD) treatment involves leveraging levodopa and adjunct therapies to address both patient-specific and pharmacologic challenges. Effective management requires coordinated care among healthcare providers to ensure comprehensive treatment strategies. Anticipating the impact of emerging therapies and upcoming changes in Medicare Part D is crucial for adapting treatment plans. These changes may influence drug accessibility and affordability, necessitating proactive adjustments in therapeutic approaches. Understanding these dynamics is essential for improving patient outcomes and maintaining the efficacy of PD management strategies.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Multisymptomatic Care in Parkinson's Disease

 is now live! Scroll down to listen, and make sure to subscribe on your favorite streaming service.

 features Dr. Anne Marie Morse, DO, a neurologist with special qualifications in child neurology and a sleep medicine specialist, best known for putting the DAMM in 

 and for always looking for digestible, actionable patient-directed sleep tips, tricks and tools to achieve optimal outcomes. Dr. Morse has joined forces with Brandon Hedgecock, DDS, D-ABDSM, a dentist and founder of Hedgecock Dental and 

; and Matthew Allard, AKA the "Sleep Connector," an experienced sleep professional with 20 years of experience helping others sleep and breathe better nightly, to break down the barriers between dentistry and medicine to develop educational content that considers the whole person and illustrate how sleep relates to lifestyle, wellness, and culture.

Sleeping Around the Podcast realized they had more to give and are a partner with 

Sleeping Around the Podcast × NeurologyLive

 for neurology-focused sleep content to allow any neurology stakeholder to add to their knowledge bank and skillset on how to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it is designed to be.

 – Connection between PD and sleep disorders

 – Overview of study assessing biomarker for EDS in Parkinson disease

 – Role of neurofilament light chain in PD

– Patient demographics and differences of NfL increases 

. Check out the links below to subscribe on your preferred podcast platform.

DAMM Good Sleep

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of a newly published study highlighting extracellular vesicle-associated miRNA features that could be diagnostically informative of RBD in patients with Parkinson disease.

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Watch the video version of this episode here. 

Dyskinesia: Importance of Giving Patients More Good “On- Time" in Parkinson’s Disease

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

 – Sleep disturbances as major feature of PD

 – Parkinson-related pathological changes

Sleeping Around the Podcast × NeurologyLive brings you a scientific overview of the crossover between Parkinson disease and sleep disorders. 

Sleeping Around the Podcast × NeurologyLive: Parkinson Disease Awareness Month

To watch the full video episode, follow this link. 

Widening the Therapeutic Window in the Management of Parkinson’s Disease

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

 to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 93, "Caring for Women With Parkinson Disease," features an exclusive interview with 

, an assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute, who spoke with us about the current landscape of care for women with Parkinson disease (PD), how the approach to their care can differ from men, the major gaps around education and treatment for these women, and much more.

, a streaming channel from MJH Life Sciences

. Check out new content and shows every day, only at

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Issues Complete Response Letter to Amneal for Parkinson Agent IPX203

FDA Grants Traditional Approval to Lecanemab as Therapy for Early-Stage Alzheimer Disease

Medicare Expands Coverage for Fully Approved Alzheimer Agent Lecanemab

FDA Approves Image Guided Programming Software for Vercise Deep Brain Stimulation Systems

 – The presentation of Parkinson disease for women

 – Nonmotor symptoms that can create challenges  for diagnosis

 – OFF episodes and dyskinesia in women vs men

 – Being attentive to patient needs in treatment

 – The daily impact of Parkinson disease

 – Encouraging women with Parkinson to participate in trials

– Conversations in areas of limited knowledge

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jill Farmer, DO, MPH. [LISTEN TIME: 28 minutes]

Episode 93: Caring for Women With Parkinson Disease

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 81, "Widening the Therapeutic Window in Parkinson Disease," features an exclusive interview with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease, some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. 

Neurelis Files IND for Potentially First Therapy to Treat Cerebral Cavernous Malformations

CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine

FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data

FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845

Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy

 – Lingering unmet needs in Parkinson disease management

 – The advances in identifying therapeutic targets in PD

 – Bridging the gap to more effective long-term treatment

 – Overview of IPX203 and its potential to treat PD

 – Safety profile of IPX203 in clinical development

 – The importance of addressing dose-wearing off

 podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]

Episode 81: Widening the Therapeutic Window in Parkinson Disease

Episode 78, "A Virtual Reality Platform for Parkison Disease," features an exclusive interview with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (CC-VRS) platform works towards that, among other topics.

. Check out new episodes of a variety of shows, airing every single day, only on

International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype

Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation

Duchenne Gene Therapy SRP-9001 Wins Priority Review

Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses

Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

Episode Breakdown

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Episode 78: A Virtual Reality Platform for Parkinson Disease

MeiraGTx's AAV-GAD gene therapy receives FDA RMAT designation, promising innovative treatment for Parkinson's disease through targeted brain infusion.

Gene Therapy AAV-GAD Gains Regenerative Medicine Advanced Therapy Designation as Potential Parkinson Treatment

Early findings from the ASPIRO trial showed ANPD001 was safe, well-tolerated, and led to marked improvements in motor symptoms and daily functioning.

Parkinson Cell Therapy ANPD001 Generates Promising Early-Stage Phase 1/2 Data

STN-FUS provided more sustained tremor reduction, improved bradykinesia, and had a higher responder rate at 12 months, though both treatments showed comparable reductions in rigidity and motor scores.

Subthalamic Focused Ultrasound Outperforms Ventral Intermediate Thalamotomy in Sustained Parkinson Disease Tremor Control

Explore the latest advancements in cell and gene therapies for Parkinson disease, featuring cutting-edge treatments and clinical trial updates from top innovators in the field.

The Next Frontier in Parkinson Disease Care: Exploring Gene and Cell Therapies

The REGENERATE-PD trial is a phase 2 study assessing the safety and efficacy of the investigational gene therapy AB-1005 in patients with moderate-stage Parkinson disease.

Investigating Therapeutic Potential of Gene Therapy AB-1005 in Moderate Parkinson Disease: The REGENERATE-PD Trial

Panelists discuss how challenges in prescribing subcutaneous infusion systems might affect patient adherence and device management, best practices for patient education, and what additional data would benefit clinicians implementing newer Parkinson disease treatments.

Challenges in and Advice for Prescribing Subcutaneous Infusion Systems for Parkinson Disease

Video content above is prompted by the following: 

Challenges and Best Practices in Prescribing Subcutaneous Infusion Systems

Challenges in Prescribing Subcutaneous Infusion Systems:

 Physicians may face several challenges when prescribing subcutaneous infusion systems, especially regarding patient adherence and effective device management. Key challenges include:

: Some patients may struggle with the technical aspects of using infusion systems, including proper device setup, administration, and troubleshooting.

: Patients may have concerns about pain, discomfort, or the aesthetic impact of wearing infusion devices. This can lead to nonadherence or inconsistent use.

: Patients may find it difficult to integrate infusion therapy into their daily routines, especially with systems requiring frequent adjustments or long-term use.

: Infusion systems can malfunction or experience issues like occlusions, alarms, or interruptions in delivery, requiring the patient to manage potential device failures.

: Physicians must guide patients on how to adjust infusion settings or respond to any irregularities in the infusion process. This requires consistent follow-up to ensure proper therapy delivery and avoid complications like underdosing or overdosing.

: Proper handling and storage of medication and the infusion devices are essential to maintain efficacy and avoid contamination or damage.

Best Practices for Educating Patients on Subcutaneous Infusion Systems:

 Effective patient education is critical for ensuring that patients are well-informed about the use, benefits, and potential corollaries of 24-hour vs 16-hour subcutaneous infusion systems. Best practices include:

Physicians should tailor education to the patient’s individual needs, considering factors like age, cognitive abilities, and technical aptitude.

Clear instructions on how to use the infusion device should be provided in both verbal and written formats, accompanied by demonstration sessions. Videos or online resources can be helpful to reinforce key points.

: These systems typically offer continuous, steady medication delivery. Patients should understand the benefit of stable drug levels and how this can lead to more consistent symptom management.

: While they offer more flexibility, these systems may require more active involvement from the patient in terms of timing and monitoring. Educating patients on the trade-off between autonomy and the need for consistent administration is essential.

Parkinson Disease

Latest News